Murcia

• Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor tolebrutinib (SAR442168) (PERSEUS) Ended
  2024-514495-41-00 5 2020-11-04 Primary Progressive Multiple Sclerosis
• Heart Failure study with Danicamtiv in patients with reduced heart function caused by gene mutation Ended
  2023-505492-68-00 4 2020-10-06 Primary Dilated Cardiomyopathy Due to Either MYH7 o TTN Variants
• Study to evaluate the effect of metformin in the prevention of hyperglycemia in HR[+]/HER2[–] PIK3CA-mutated advanced breast cancer patients … Ended
  2024-511295-33-00 4 2020-08-13 Study to evaluate the effect of metformin in the prevention of hypergl
• An open-label study evaluating ofatumumab treatment effectiveness and PROs in subjects with RMS transitioning from fumarate-based RMS approv … Ended
  2023-507493-41-00 5 2020-08-04 relapsing multiple sclerosis (RMS)
• A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Ri … Ended
  2023-504036-17-00 5 2020-05-07 Chronic Lymphocytic Leukemia (CLL)
• Multicenter, Open-Label, Single Arm, Phase II Exploratory Study to Evaluate the Reinduction and second stop of TKI with Ponatinib in CML in … Ended
  2023-508993-27-00 4 2020-01-17 Chronic myelogenous leukemia
• A Long-term Safety Extension Study of Mavacamten (MYK-461) in Adults with Hypertrophic Cardiomyopathy Who Have Completed the MAVERICKHCM (MY … Ended
  2022-502858-14-00 5 2019-09-05 Hypertrophic cardiomyopathy
• A study comparing current standard therapies with fedratinib for the treatment of myelofibrosis (either diagnosed alone or after polycythemi … Ended
  2024-511972-33-00 5 2019-08-05 Primary myelofibrosis, post-polycythemia vera myelofibrosis , or post-
• Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke Ended
  2023-503673-38-00 5 2019-05-24 Adults at high risk of cardiovascular events without prior MI or strok
• The safety and efficacy of Alpha-1 Antitrypsin (AAT) for the prevention of graft‑versus-host disease (GVHD) in patients receiving hematopoie … Ended
  2024-511164-92-00 10 2019-05-17 Acute Graft versus host disease
• Chemotherapy plus Paclitaxel with Bevacizumab and Atezolizumab versus Chemotherapy plus Paclitaxel and Bevacizumab in Carcinoma of the Cervi … Ended
  2024-514179-17-00 5 2018-10-02 Metastatic (stage IVB), Persistent, or Recurrent Carcinoma of the Cerv
• Phase 3 Trial of Maintenance with Selinexor/ Placebo After Combination Chemotherapy for Patients with Advanced or Recurrent Endometrial Canc … Ended
  2024-513167-68-00 5 2017-11-29 endometrial cancer
• A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advan … Ended
  2023-506487-13-00 5 Hormone receptor-positive, her2-negative advanced/metastatic breast ca
• A Phase 3 Study to Evaluate the Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants with Relapsed or Ref … Ended
  2023-509472-42-00 5 Relapsed and/or Refractory Multiple Myeloma
• Normal saline versus lactated Ringer’s solution for acute pancreatitis resuscitation, an open-label multicenter randomized controlled trial: … Ended
  2023-509879-16-00 6 Acute pancreatitis
• Phase 3 Study of Tamibarotene Plus Azacitidine in Patients Selected for RARA-positive Higher-risk MDS (SELECT-MDS-1) Ended
  2023-510361-97-00 5 Newly Diagnosed RARA-positive Adult Patients with Higher-risk Myelodys
• Study of the Effectiveness and Safety of Acasunlimab Alone or With Pembrolizumab in treating Advanced Melanoma of the Skin That Has Returned … Ended
  2025-520468-16-00 4 Cutaneous Melanoma, Relapsed/Refractory, Locally Advanced Unresectable
• A PHASE II TRIAL EVALUATING THE SAFETY AND EFFICACY OF THE COMBINATION OF ZIMBERELIMAB, DOMVANALIMAB, AND SACITUZUMAB GOVITECAN AS FIRST-LIN … Ended
  2025-521489-80-00 4 PD-L1 POSITIVE ADVANCED TRIPLE-NEGATIVE BREAST CANCER

Showing 409–426 of 426 trials